G. MICHAEL LOPEZ: Open Payments
NPI 1003973397 · LAS VEGAS, NM. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$564 in 26 payments from 11 companies in 2025. Trend: 2023 $342 · 2024 $408 · 2025 $564
Food & beverage: $564
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $173 |
| Merck Sharp & Dohme LLC | 5 | $82 |
| Novo Nordisk Inc | 4 | $63 |
| AstraZeneca Pharmaceuticals LP | 3 | $57 |
| Lilly USA, LLC | 2 | $40 |
| Indivior Inc. | 2 | $40 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $29 |
| GlaxoSmithKline, LLC. | 1 | $24 |
| Neurocrine BioSciences, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
Products named: Kerendia, VERQUVO, MOUNJARO, SUBLOCADE, Ozempic, JARDIANCE, BREZTRI, NUCALA.
Industry payments across NM — which companies pay providers there.
